Lunit acquires Volpara Health Technologies to advance AI in cancer diagnostics

Lunit, a leader in AI-powered solutions for cancer diagnostics and therapeutics, has completed its acquisition of Volpara Health Technologies, a global frontrunner in medical software for breast cancer screening. This strategic acquisition, finalized within an impressive eight-month timeline, significantly enhances Lunit‘s capabilities in AI-driven cancer diagnostics by integrating Volpara’s advanced breast health platform.

Expanding Capabilities and Market Reach

With the addition of Volpara’s technologies, such as breast density assessment and screening workflow enhancements, Lunit now offers a comprehensive AI suite that improves every aspect of breast screening. This acquisition not only bolsters Lunit’s detection capabilities but also streamlines administrative processes, positioning the company as a leader in the market with a robust industry reputation.

Looking forward, Lunit plans to leverage the synergy with Volpara to develop autonomous AI models that can independently screen, detect, and diagnose cancer. This advancement represents a significant leap forward in cancer diagnostics, potentially transforming patient care on a global scale.

Strategic Entry into the US Market

Volpara’s established presence in over 2,000 U.S. medical sites provides Lunit a strategic foothold in the American healthcare market, the largest in the world. The U.S. AI healthcare market is projected to grow from USD 2.9 billion in 2022 to USD 51.3 billion by 2030, driven by the demand for efficient healthcare services and potential cost savings. Additionally, the recent lowering of the breast cancer screening age by the US Preventive Services Task Force is expected to increase screening demand significantly, offering a substantial opportunity for Lunit.

Conversely, Lunit plans to expand Volpara’s solutions across Europe, Asia, the Middle East, and South America, where it has already established a strong market presence. This strategic expansion is expected to greatly enhance the group’s global reach and solidify its position as a leader in the industry.

Industry Leaders’ Perspectives

“We are thrilled to welcome Volpara into the Lunit family. Today, we take a monumental step towards revolutionizing our approach to cancer care,” stated Brandon Suh, CEO of Lunit. “This merger enables us to develop and deliver innovative, life-saving solutions that meet critical needs in cancer diagnostics.”

Teri Thomas, CEO of Volpara, added, “This merger represents an exciting opportunity to enhance our impact on global healthcare. By integrating our innovative breast screening technology with Lunit’s AI capabilities, we aim to set new standards in cancer diagnostics and drive forward advancements that will benefit healthcare providers and patients globally.”